191 related articles for article (PubMed ID: 7516401)
21. Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening SA
J Urol; 1999 Aug; 162(2):502-3. PubMed ID: 10411077
[No Abstract] [Full Text] [Related]
22. Prostate-specific antigen and other prostate cancer markers.
Stenman U; Finne P; Zhang W; Leinonen J
Urology; 2000 Dec; 56(6):893-8. PubMed ID: 11113726
[No Abstract] [Full Text] [Related]
23. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
[TBL] [Abstract][Full Text] [Related]
24. High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
Obralic N; Kulovac B
Bosn J Basic Med Sci; 2011 Nov; 11(4):223-7. PubMed ID: 22117828
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
Lehmann K; Plas E; Gautschi K; Hauri D
Urol Int; 1994; 52(3):159-61. PubMed ID: 7515534
[TBL] [Abstract][Full Text] [Related]
26. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
[TBL] [Abstract][Full Text] [Related]
29. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
30. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
[TBL] [Abstract][Full Text] [Related]
31. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
Yesner R; Kelly LJ; Chan YK
Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
[TBL] [Abstract][Full Text] [Related]
32. PSA scores: should we use a lower threshold?
Carter HB
Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):6. PubMed ID: 15602780
[No Abstract] [Full Text] [Related]
33. [Improving the specificity of PSA's in the diagnostic gray zone 4-10 ng/ml by human glandular kallikrein].
Recker F; Kwiatowski MK; Piironen T
Urologe A; 1998 Jul; 37(4):421-3. PubMed ID: 9738296
[No Abstract] [Full Text] [Related]
34. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
[TBL] [Abstract][Full Text] [Related]
35. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management.
Benson MC; Olsson CA
Cancer; 1994 Sep; 74(6):1667-73. PubMed ID: 7521783
[TBL] [Abstract][Full Text] [Related]
36. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
[TBL] [Abstract][Full Text] [Related]
37. [Status of PSA determination for early detection of prostate carcinoma].
Hammerer P; Huland H
Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
[TBL] [Abstract][Full Text] [Related]
38. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
[TBL] [Abstract][Full Text] [Related]
39. [Importance of specific prostatic antigen to prostatic volume ratio in the selection of patients for ultrasonography-guided biopsy of the prostate].
Veneziano S; Pavlica P; Querzè R; Viglietta G; Trenta A
Radiol Med; 1991 Jun; 81(6):857-60. PubMed ID: 1713333
[TBL] [Abstract][Full Text] [Related]
40. MMP26: A potential biomarker for prostate cancer.
Cheng T; Li F; Wei R; Lv MQ; Zhou Y; Dai Y; Yuan Y; Jiang GY; Ma D; Gao QL
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
